Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
- What preclinical evidence is there which showcases the potential for NRAS-targeting programs?
- How to selectively target NRAS and minimize off-target effects?
- How to develop a successful patient stratification strategy and clinical trial design for RAS-mutant cancer programs?